<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Quinagolide (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Quinagolide (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Quinagolide (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11899" href="/d/html/11899.html" rel="external">see "Quinagolide (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868765"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Norprolac [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F4800586"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Hyperprolactinemia Agent, Dopamine (D2) Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F4800623"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1f49b449-84cb-4721-8576-d938c215d749">Hyperprolactinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;">
<b>Hyperprolactinemia:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:2em;">Initial: 0.025 mg once daily for 3 days followed by 0.05 mg once daily for 3 days (starter pack).</p>
<p style="text-indent:-2em;margin-left:2em;">Maintenance (beginning on day 7): 0.075 mg once daily; if needed, a further stepwise titration may occur at intervals of ≥1 week; usual maintenance range: 0.075 to 0.15 mg/day; if higher doses are needed, titrate in increments of 0.075 to 0.15 mg/day at intervals ≥4 weeks up to a maximum of 0.9 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991551"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use in contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50988698"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use in contraindicated.</p></div>
<div class="block doe drugH1Div" id="F4801577"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F4800595"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, fatigue, headache</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (2%), hypotension (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (3%), abdominal pain (3%), anorexia (2%), constipation (3%), dyspepsia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (2%), malaise (1%), sedated state (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia(3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye disease (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing, palpitations, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Acute psychosis, drowsiness, emotional lability, lack of concentration</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased creatinine phosphokinase in blood specimen, increased serum potassium, increased serum triglycerides</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, neutropenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum bilirubin, increased serum transaminases</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Withdrawal syndrome (dopamine agonist withdrawal syndrome [DAWS]) (Health Canada 2021)</p></div>
<div class="block coi drugH1Div" id="F4800591"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to quinagolide or any component of the formulation; hepatic or renal impairment</p></div>
<div class="block war drugH1Div" id="F4800592"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression (eg, sudden sleep onset and somnolence) particularly in patients with Parkinson disease which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). Use with other agents known to induce somnolence or sleep may be expected to potentiate these risks. Dose reduction or therapy discontinuation may be needed if sudden onset of sleep develops.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal distress: Use may be associated with frequent (but transient) nausea and vomiting early in therapy; during initial therapy, premedication with a peripheral dopamine antagonist may alleviate these effects and improve tolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Hypotensive episodes along with syncope may occur with the onset of therapy; monitor blood pressure early in therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impulse control disorders: Monitor for development of impulse control disorders (eg, pathological gambling, increased libido, hypersexuality, compulsive spending, or binge and compulsive eating). Consider dose reduction or tapered discontinuation if symptoms develop.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with prior psychotic disorders; the onset of acute psychosis has rarely been observed with use of quinagolide (reversible upon discontinuation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiotherapy/Surgery: Treatment with quinagolide may not exclude the need for radiation and/or surgical intervention if appropriate.</p></div>
<div class="block prod-avail drugH1Div" id="F11234287"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040747"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block dinfoc drugH1Div" id="F52868766"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norprolac: 0.025 mg [DSC], 0.05 mg [DSC], 0.075 mg [DSC], 0.15 mg [DSC]</p></div>
<div class="block adm drugH1Div" id="F4800626"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer once daily with snack at bedtime. Nausea and vomiting may be alleviated by premedicating with a peripheral dopamine antagonist.</p></div>
<div class="block use drugH1Div" id="F2638239"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the US</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperprolactinemia:</b> Treatment of hyperprolactinemia (idiopathic or due to a prolactin-secreting pituitary microadenoma or macroadenoma)</p></div>
<div class="block mst drugH1Div" id="F48826278"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Quinagolide may be confused with quinapril</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F4800603"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F4800602"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Quinagolide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: May diminish the therapeutic effect of Quinagolide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: Quinagolide may enhance the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May diminish the therapeutic effect of Quinagolide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May diminish the therapeutic effect of Quinagolide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Quinagolide may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Quinagolide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Quinagolide may diminish the therapeutic effect of Sulpiride. Sulpiride may diminish the therapeutic effect of Quinagolide. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49321701"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Quinagolide is approved for the treatment of hyperprolactinemia. Increased prolactin concentrations due to a prolactinoma may cause galactorrhea, amenorrhea, oligomenorrhea, or luteal phase insufficiency (ES [Melmed 2011]; ESE [Luger 2021]). Fertility may be restored with treatment; contraception should be used by patients of reproductive potential who do not wish to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment with a dopamine agonist is recommended for patients with a prolactinoma who are trying to conceive. However, quinagolide is not preferred if treatment is needed during pregnancy (ES [Melmed 2011]; ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Normalizing prolactin concentrations during dopamine agonist treatment for a micro- or macroadenoma also improves fertility by restoring nocturnal penile tumescence, sperm count, and sperm motility (ES [Melmed 2011]).</p></div>
<div class="block pri drugH1Div" id="F4800587"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Quinagolide is approved for the treatment of hyperprolactinemia. Information related to the use of quinagolide during pregnancy is limited (ESE [Luger 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Based on known safety data, if treatment of a prolactinoma during pregnancy is required, a dopamine agonist other than quinagolide may be preferred (ES [Melmed 2011]; ESE [Luger 2021]). Discontinue use with confirmed pregnancy unless medically necessary to continue. The reinstitution of therapy may be necessary in patients who display symptoms of tumor enlargement (headaches, visual field changes).</p>
<p style="text-indent:0em;margin-top:2em;">Serum prolactin concentrations are increased during pregnancy; monitoring prolactin levels may not be reliable for tumor progression (ES [Melmed 2011]; ESE [Luger 2021]).</p></div>
<div class="block brc drugH1Div" id="F4800590"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Quinagolide suppresses lactation.</p></div>
<div class="block mop drugH1Div" id="F4800628"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Prolactin levels; blood pressure; sedation, mental changes</p></div>
<div class="block pha drugH1Div" id="F4800609"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Selective dopamine D<sub>2</sub> receptor agonist that exerts a direct inhibitory effect on cells (lactotrophs) in the anterior pituitary gland which synthesize and secrete prolactin; not an ergot alkaloid</p></div>
<div class="block phk drugH1Div" id="F4800611"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 2 hours; maximum effect: 4 to 6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: &gt;24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 100 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~90%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; via conjugation (glucuronide and sulfate)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 4%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 11.5 hours; steady state: 17 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 30 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50%); feces (40%); &gt;95% as metabolites</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4369778"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Norprolac | Quinagolide</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Norprolac | Norprolac Starter Pack</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Norprolac</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-16452531">
<a name="16452531"></a>Barlier A and Jacquet P, “Quinagolide − A Valuable Treatment Option for Hyperprolactinaemia,” <i>Eur J Endocrinol</i>, 2006, 154(2):187-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/16452531/pubmed" id="16452531" target="_blank">16452531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16411066">
<a name="16411066"></a>Bronstein M, “Prolactinomas and Pregnancy”, <i>Pituitary</i>, 2005, 8(1):31-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/16411066/pubmed" id="16411066" target="_blank">16411066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10931080">
<a name="10931080"></a>DiSarno A, Landi ML, Marzullo P, et al, “The Effect of Quinagolide and Cabergoline, Two Selective Dopamine Receptor Type 2 Agonists, in the Treatment of Prolactinomas,” <i>Clin Endocrinol </i> (Oxf), 2000, 53(1):53-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/10931080/pubmed" id="10931080" target="_blank">10931080</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Health Canada. Summary safety review - dopamine agonists - assessing the potential risk of dopamine agonist withdrawal syndrome. <a href="https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00269" target="_blank">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00269</a>. Updated June 8, 2021. Accessed June 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34425558">
<a name="34425558"></a>Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. <i>Eur J Endocrinol</i>. 2021;185(3):G1-G33. doi:10.1530/EJE-21-0462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/34425558/pubmed" id="34425558" target="_blank">34425558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21296991">
<a name="21296991"></a>Melmed S, Casanueva FF, Hoffman AR, et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2011;96(2):273-288. doi:10.1210/jc.2010-1692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/21296991/pubmed" id="21296991" target="_blank">21296991</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Norprolac (quinagolide) [product monograph]. Toronto, Ontario, Canada: Ferring, Inc; October 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11788012">
<a name="11788012"></a>Schultz PN, Ginsberg L, McCutcheon IE, et al, “Quinagolide in the Management of Prolactinoma,” <i>Pituitary</i>, 2000, 3(4):239-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/quinagolide-united-states-not-available-drug-information/abstract-text/11788012/pubmed" id="11788012" target="_blank">11788012</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10227 Version 141.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
